Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
Rhea-AI Summary
Aspire Biopharma (Nasdaq:ASBP) announced on March 17, 2026 that subsidiary Buzz Bomb Caffeine Company appointed John Choe as Western Sales Director. Choe is described as a 25-year industry veteran with prior roles at Yerbaé (2016–2025) and a reported 70% sales increase.
The announcement highlights Choe's experience in retail and beverage distribution, DSD and wholesale relationships, multilingual skills, and his MBA and BS degrees as assets to scale Buzz Bomb's western U.S. sales efforts.
Positive
- None.
Negative
- None.
News Market Reaction – ASBP
On the day this news was published, ASBP declined 10.21%, reflecting a significant negative market reaction. This price movement removed approximately $434K from the company's valuation, bringing the market cap to $4M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ASBP is down 7.15% while momentum peers NRXS, FBLG, ICU, and LEXX all show upside moves, indicating ASBP’s decline is stock-specific rather than part of a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Trade show feature | Positive | -10.0% | Buzz Bomb flagship product featured at The Health & Fitness Show 2026. |
| Mar 10 | Product launch | Positive | +1.7% | Launch of BUZZ BOMB convenience store pack for broader retail reach. |
| Mar 03 | Strategic partnership | Positive | +1.4% | Partnership with Microsize to develop rapid-delivery alprazolam powder. |
| Feb 25 | Marketing boost | Positive | +3.6% | Record social media growth and sales surge after marathon sponsorship. |
| Feb 20 | Nasdaq compliance | Positive | -2.7% | Regained full compliance with Nasdaq listing requirements. |
Recent operational and partnership news for ASBP has generally been positive, yet price reactions have been mixed, with some upbeat announcements followed by declines.
Over recent months, ASBP has highlighted Buzz Bomb marketing initiatives, new product formats, and event exposure, alongside a strategic alprazolam powder partnership and regaining full Nasdaq compliance. Prior Buzz Bomb launches and promotional events on Feb 25, Mar 10, and Mar 12, 2026 produced both gains and losses, showing inconsistent trading responses to seemingly positive updates. Today’s sales leadership appointment fits this pattern of brand- and growth-oriented news amid volatile share performance.
Market Pulse Summary
The stock dropped -10.2% in the session following this news. A negative reaction despite a leadership-focused announcement fits ASBP’s history of mixed price responses to seemingly constructive news, including Nasdaq compliance and Buzz Bomb promotions. With the price at 0.9749, just above the 52-week low of 0.9283 and far below the 35.012 high, prior filings citing substantial doubt about going concern and reliance on an equity line add context to downside volatility.
Key Terms
s.w.o.t. analysis technical
direct store delivery technical
AI-generated analysis. Not financial advice.
ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the leadership team with a distinguished career of scaling consumer brands and leading high-performance teams across the retail and beverage sectors.
Choe joins Buzz Bomb following a successful tenure as District Manager at Yerbaé (2016-2025), where he specialized in the natural energy drink category, achieving a
"John's deep expertise in the beverage and retail sectors, combined with a visionary approach to market analysis and consumer engagement, makes him an ideal leader to spearhead our sales strategy in the western United States," stated Kraig Higginson, Interim CEO of Aspire Biopharma. "The ability to build productive relationships and a creative approach to reaching both identified and untapped consumer segments will be instrumental as the brand continues to scale."
Choe's extensive background includes pivotal roles at global brands such as:
Nike (1999-2005): Managed major accounts like Nordstrom and specialized in futures ordering across Northern and Southern California.
Mars Candy (2005-2009): Led sales and merchandising efforts for massive retail outlets including Walmart, Target, and Safeway.
Bosch (2009-2012): Spearheaded training and product education for retail giants Home Depot, Lowe's, and Ace Hardware.
With 11 years of dedicated supervisory experience, Choe is a specialist in hiring, mentoring, and coaching direct reports to peak performance. His leadership style emphasizes compliance, accountability, and the development of talent. Furthermore, his fluency in Korean, Chinese, and Japanese provides a unique edge in engaging with diverse markets.
"I am thrilled to join BUZZ BOMB™ at such a pivotal moment in its growth trajectory," said John Choe. "The energy category is evolving quickly, and I look forward to leveraging my experience in retail partnerships to expand our footprint and bring Buzz Bomb's innovative products to a wider audience."
John Choe holds a Master of Business Administration from the University of Phoenix and a Bachelor of Science in Business Management from the University of Utah.
BUZZ BOMB™ Caffeine Products
To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
Who is John Choe and what role did Aspire Biopharma (ASBP) name him to on March 17, 2026?
What experience did John Choe bring to Buzz Bomb as reported by Aspire Biopharma (ASBP)?
What specific achievement from John Choe's tenure at Yerbaé did Aspire Biopharma (ASBP) highlight?
How will John Choe's appointment affect Buzz Bomb's sales strategy in the western U.S. according to Aspire Biopharma (ASBP)?
What qualifications and languages does John Choe have as noted by Aspire Biopharma (ASBP)?
